Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have earned a consensus recommendation of “Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $111.78.
A number of equities analysts have issued reports on VKTX shares. Morgan Stanley assumed coverage on Viking Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating and a $105.00 price target on the stock. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a report on Wednesday, July 31st. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target on shares of Viking Therapeutics in a research note on Monday, June 17th. Raymond James increased their price objective on shares of Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $120.00 target price on shares of Viking Therapeutics in a research report on Tuesday, June 4th.
Check Out Our Latest Analysis on Viking Therapeutics
Insider Buying and Selling at Viking Therapeutics
Hedge Funds Weigh In On Viking Therapeutics
Several institutional investors have recently modified their holdings of VKTX. Massmutual Trust Co. FSB ADV purchased a new position in Viking Therapeutics in the first quarter worth $25,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Viking Therapeutics during the 2nd quarter worth $27,000. Lindbrook Capital LLC raised its stake in shares of Viking Therapeutics by 370.7% during the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 278 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in shares of Viking Therapeutics in the 4th quarter worth about $37,000. Finally, LifeSteps Financial Inc. bought a new position in Viking Therapeutics during the first quarter valued at about $37,000. 76.03% of the stock is owned by institutional investors.
Viking Therapeutics Stock Down 0.5 %
Shares of NASDAQ VKTX opened at $56.71 on Friday. The company has a market capitalization of $6.25 billion, a PE ratio of -60.98 and a beta of 1.03. The firm has a fifty day simple moving average of $54.00 and a 200 day simple moving average of $59.53. Viking Therapeutics has a twelve month low of $8.28 and a twelve month high of $99.41.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. During the same period last year, the company earned ($0.19) earnings per share. As a group, equities analysts expect that Viking Therapeutics will post -0.99 earnings per share for the current fiscal year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
- Five stocks we like better than Viking Therapeutics
- What is a Bond Market Holiday? How to Invest and Trade
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- How to Calculate Inflation Rate
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.